G protein-coupled receptors (GPCRs) have a central role in a myriad of physiological functions and their dysregulation underlies some of the most prevalent human diseases. They control cell behaviour and cell fate by recruiting and activating intracellular molecules such as heterotrimeric G proteins and arrestins, both of which take active roles in GPCR signalling. G proteins have been viewed as the main signal transducers, whereas arrestins were originally associated with signalling desensitization. Nevertheless, some studies have demonstrated G protein-independent roles of arrestins in GPCR signal transduction. In this Comment, we highlight recent key findings obtained with genome-edited cells to suggest that arrestins — rather than being active transducers in their own right — are key modulators of G protein-initiated signal transmission, thereby shaping and fine-tuning dynamic GPCR responses in space and time.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reply to: How carvedilol does not activate β2-adrenoceptors
Nature Communications Open Access 30 November 2023
-
Selective Signal Capture from Multidimensional GPCR Outputs with Biased Agonists: Progress Towards Novel Drug Development
Molecular Diagnosis & Therapy Open Access 20 May 2022
-
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
Nature Communications Open Access 19 June 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. 17, 243–260 (2018).
O’Hayre, M. et al. Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK. Sci Signal. 10, eaal3395 (2017).
Grundmann, M. et al. Lack of β-arrestin signaling in the absence of active G proteins. Nat. Commun. 9, 341 (2018).
Latorraca, N. R. et al. Molecular mechanism of GPCR-mediated arrestin activation. Nature 557, 452–456 (2018).
Eichel, K. et al. Catalytic activation of β-arrestin by GPCRs. Nature 557, 381–386 (2018).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gutkind, J.S., Kostenis, E. Arrestins as rheostats of GPCR signalling. Nat Rev Mol Cell Biol 19, 615–616 (2018). https://doi.org/10.1038/s41580-018-0041-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41580-018-0041-y
This article is cited by
-
Reply to: How carvedilol does not activate β2-adrenoceptors
Nature Communications (2023)
-
Selective Signal Capture from Multidimensional GPCR Outputs with Biased Agonists: Progress Towards Novel Drug Development
Molecular Diagnosis & Therapy (2022)
-
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides
Nature Communications (2020)